Literature DB >> 360522

Immunological donor pretreatment in combination with pulsatile preservation in cadaveric renal transplantation.

H Zincke, J E Woods, A U Khan, K E Holley, F J Leary.   

Abstract

The extended experience on the efficacy of pretreating the cadaveric renal allograft donor by means of large doses of cyclophosphamide and methylprednisolone (group A, 36 kidneys) was compared with the experience regarding untreated renal allografts (group B, 32 kidneys). Kidneys in both groups were perfused by pulsatile means using cryoprecipitated plasma. There was a significant difference in allograft survival (72% in group A versus 36% in group B at 3 years by actuarial means). Also, large doses of cyclophosphamide and methylprednisolone as pretreatment did not cause any detrimental effect to the allograft kidney when used in combination with cryoprecipitated plasma and pulsatile perfusion.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 360522     DOI: 10.1097/00007890-197810000-00001

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Developing ways of reducing allograft immunogenicity.

Authors:  R D Guttmann
Journal:  Can Med Assoc J       Date:  1981-01-15       Impact factor: 8.262

2.  Photochemical donor pretreatment in clinical kidney transplantation--preliminary report.

Authors:  H Oesterwitz; D Scholz; J Kaden; G May; M Mebel; R Schirrow; W Blank
Journal:  Urol Res       Date:  1987

3.  Factors associated with outcome of renal transplantation.

Authors:  G E McKeown-Eyssen; R D Guttmann
Journal:  Can Med Assoc J       Date:  1983-12-01       Impact factor: 8.262

4.  Steroid pretreatment of organ donors does not impact on early rejection and long-term kidney allograft survival: Results from a multicenter randomized, controlled trial.

Authors:  Roman Reindl-Schwaighofer; Alexander Kainz; Kira Jelencsics; Andreas Heinzel; Gabriela Berlakovich; Ádám Remport; Georg Heinze; Robert Langer; Rainer Oberbauer
Journal:  Am J Transplant       Date:  2019-02-01       Impact factor: 8.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.